Chardan analyst Geulah Livshits lowered the firm’s price target on Senti Bio to $8 from $12 and keeps a Buy rating on the shares after the company announced a pipeline prioritization that will see it internally focus on advancing CAR-NK candidates SENTI-202 in acute myeloid leukemia and SENTI-401 in colorectal cancer while seeking a partner for SENTI-301A in hepatocellular carcinoma.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SNTI:
- Senti Bio sees cash runway through at least 1Q24
- Senti Bio does not intend to invest in development of SENTI-301A
- Senti Bio to focus resources on SENTI-202, SENTI-401
- Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance
- Senti Bio to Present at 41st Annual J.P. Morgan Healthcare Conference
